⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL8931675 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL4237662 | 0.68 | — | — | |
| SCHEMBL3590698 | 0.64 | NOTUM (0.33) | — | |
| SCHEMBL4642951 | 0.58 | — | — | |
| SCHEMBL11797642 | 0.58 | — | — | |
| SCHEMBL11016613 | 0.57 | — | — | |
| SCHEMBL30812390 | 0.57 | — | — | |
| SCHEMBL3630410 | 0.57 | — | — | |
| SCHEMBL3930550 | 0.56 | PYGM (0.31) | — | |
| SCHEMBL18032691 | 0.56 | GSK3A (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100239563-A1 | PHARMACEUTICAL COMPOSITION FOR THE PROPHYLAXIS AND/OR TREATMENT OF VIRAL DISEASES | LUDWIG STEPHAN | 2010-09-23 | — | — | US | claimed |
| EP-1707193-A2 | Pharmaceutical composition for the prophylaxis and/or treatment of viral diseases | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH (DE) | 2006-10-04 | — | — | EP | claimed |
| EP-1086105-A1 | FUSED AZEPINONE CYCLIN DEPENDENT KINASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-03-28 | — | — | EP | claimed |
| WO-1999065910-A9 | FUSED AZEPINONE CYCLIN DEPENDENT KINASE INHIBITORS | US HEALTH (US) | 2000-03-16 | — | — | WO | claimed |
| WO-1999065910-A1 | FUSED AZEPINONE CYCLIN DEPENDENT KINASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-23 | — | — | WO | claimed |
| WO-2021188772-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PATHOLOGIC PAIN ASSOCIATED WITH MALIGNANT GROWTH DISORDER | DUKE UNIVERSITY (US) | 2021-09-23 | — | — | WO | disclosed |
| CN-105358677-A | Compositions and methods for epithelial stem cell expansion and culture | BRIGHAM & WOMENS HOSPITAL | 2016-02-24 | — | — | CN | disclosed |
| CN-104379136-A | Method of prevention of neurological diseases | INT STEM CELL CORP | 2015-02-25 | — | — | CN | disclosed |
| EP-2827869-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | Brown, Dennis (US) | 2015-01-28 | — | — | EP | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| CN-103446138-A | Neuroendocrine tumor treatment using mtor inhibitors | NOVARTIS AG | 2013-12-18 | — | — | CN | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| EP-1707193-A2 | Pharmaceutical composition for the prophylaxis and/or treatment of viral diseases | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH (DE) | 2006-10-04 | — | — | EP | disclosed |
| WO-2002089779-A2 | COMBINED PREPARATION FOR THE PROPHYLAXIS AND/OR THERAPY OF NERVE CELL AND/OR GLIA CELL DAMAGE USING A NOVEL METHOD OF TREATMENT | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH (DE) | 2002-11-14 | — | — | WO | disclosed |
| EP-1255551-A1 | USE OF PAULLONE DERIVATIVES FOR MAKING MEDICINES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001060374-A1 | USE OF PAULLONE DERIVATIVES FOR MAKING MEDICINES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2001-08-23 | — | — | WO | disclosed |
| EP-1086105-A1 | FUSED AZEPINONE CYCLIN DEPENDENT KINASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999065910-A9 | FUSED AZEPINONE CYCLIN DEPENDENT KINASE INHIBITORS | US HEALTH (US) | 2000-03-16 | — | — | WO | disclosed |
| WO-1999065910-A1 | FUSED AZEPINONE CYCLIN DEPENDENT KINASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-23 | — | — | WO | disclosed |
| US-5674866-A | Antiallergic imidazoazepines | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-10-07 | — | — | US | disclosed |